EyePoint Pharmaceuticals Inc EYPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EYPT is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $17.50
- Day Range
- $16.71–17.80
- 52-Week Range
- $5.32–30.99
- Bid/Ask
- $16.90 / $17.99
- Market Cap
- $879.51 Mil
- Volume/Avg
- 1.5 Mil / 994,872
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 144
- Website
- https://www.eyepointpharma.com
Comparables
Valuation
|
Metric
|
EYPT
|
TARS
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.25 | 5.71 | 3.42 |
Price/Sales | 14.92 | 55.32 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
EYPT
TARS
EWTX
Financial Strength
|
Metric
|
EYPT
|
TARS
|
EWTX
|
|---|---|---|---|
Quick Ratio | 5.25 | 6.64 | 18.98 |
Current Ratio | 5.45 | 6.93 | 19.50 |
Interest Coverage | −61.28 | −44.34 | — |
Quick Ratio
EYPT
TARS
EWTX
Profitability
|
Metric
|
EYPT
|
TARS
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −29.34% | −50.11% | −24.36% |
Return on Equity (Normalized) | −54.05% | −62.96% | −25.87% |
Return on Invested Capital (Normalized) | −48.97% | −58.53% | −29.82% |
Return on Assets
EYPT
TARS
EWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yxrnvqyzg | Gcmp | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rvxknwcxd | Wnnbnld | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Psjbymcs | Mfszryg | $98.1 Bil | |
MRNA
| Moderna Inc | Bppbjssjq | Yzx | $38.8 Bil | |
ARGX
| argenx SE ADR | Syddbsdp | Gkx | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Gvrynskkg | Kkhjg | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xvklxrfb | Lzntjq | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sspflfwn | Lhgkqpv | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tgwmwykz | Rlgnk | $12.5 Bil | |
INCY
| Incyte Corp | Kvmbmxtk | Bxtxww | $11.9 Bil |